Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a prominent immunology company pioneering the use of advanced technological innovations to address some of the globe's most challenging infectious diseases. Combining leading scientific expertise with management prowess, Vir Biotechnology focuses on creating solutions for diseases that currently have inadequate or non-existent treatments.
Vir's core business revolves around leveraging breakthroughs in immune programming to manipulate pathogen-host interactions effectively. The company employs a multi-program, multi-platform approach, guided by rigorous science and driven by significant medical needs. Its technology platforms comprise antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).
The company's product pipeline targets severe infectious diseases, including hepatitis B (HBV), influenza A, human immunodeficiency virus (HIV), and tuberculosis (TB). Vir's revenue streams come from various sources, including collaboration revenue, contract revenue, grant revenue, and license revenue.
Vir's strategy includes internal development, collaborations, and acquisitions, positioning itself as a leader in the biotech space. Notably, Vir's recent collaboration with Brii Biosciences has led to significant advancements in the pursuit of a functional cure for HBV. Through this partnership, they have achieved Breakthrough Therapy Designations for BRII-877 and BRII-835, investigational treatments targeting HBV and chronic hepatitis D virus (HDV) infections.
The company's latest achievements highlight its focus on developing effective therapeutic regimens for chronic HBV infection, a disease affecting over 254 million people globally. With ongoing clinical trials and a commitment to scientific excellence, Vir Biotechnology is at the forefront of transforming the treatment landscape for infectious diseases.
Vir Biotechnology announced that Chief Medical Officer Phil Pang, M.D., Ph.D., will present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Conference on October 13 at 9:30 a.m. PT / 12:30 p.m. ET. A live webcast will be available via the Investors section of the Vir website and will be archived for 30 days post-event.
Vir focuses on using advanced technologies to combat serious infectious diseases, with ongoing projects targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its Chief Medical Officer, Phil Pang, M.D., Ph.D., will present at the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference on October 6, 2021, at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast of the presentation will be available on the company's Investors page and archived for 30 days. Vir focuses on immunological solutions for infectious diseases, with a pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced that CEO George Scangos, Ph.D., will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 9:30 a.m. PT / 12:30 p.m. ET. Investors can access a live webcast from the Investors section of the Vir website, which will also be archived for 30 days after the event. The company emphasizes the importance of monitoring its website for material information and updates on its development pipeline, which focuses on serious infectious diseases.
Vir Biotechnology announces that CFO Howard Horn will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 a.m. PT / 7:00 a.m. ET. The presentation will be available via live webcast on the company's website and archived for 30 days.
Vir focuses on leveraging immunologic insights and technology to combat infectious diseases, with a development pipeline targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology has received the first marketing authorization for its monoclonal antibody, sotrovimab, in Australia. This approval from the Australian Therapeutic Goods Administration allows sotrovimab, branded as Xevudy®, to be used in adults and adolescents with COVID-19 at risk of severe outcomes. Sotrovimab has already been authorized for emergency use in the U.S. and received favorable opinions in other regions. Vir is collaborating with GlaxoSmithKline to distribute sotrovimab, which shows efficacy against current SARS-CoV-2 variants.
Vir Biotechnology, Inc. (Nasdaq: VIR) announced robust second-quarter 2021 results, achieving total revenues of $177.1 million, a significant increase from $67.0 million YoY. Key developments include the emergency use authorization of monoclonal antibody sotrovimab for high-risk COVID-19 patients and positive data showing its efficacy against prevalent variants. The company also advanced its hepatitis B portfolio, initiating multiple clinical trials. Notably, net income reached $61.8 million, or $0.48 per share, reversing a loss from the previous year.
Vir Biotechnology and GlaxoSmithKline have entered a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, a monoclonal antibody treatment for COVID-19. This agreement aims to provide rapid access to sotrovimab for high-risk patients in participating EU Member States. Sotrovimab has shown a 79% reduction in hospitalizations/deaths in clinical trials. The companies are also pursuing ongoing evaluations to ensure effectiveness against new virus variants, emphasizing the urgent need for effective treatments amid the ongoing pandemic.
Vir Biotechnology (Nasdaq: VIR) announced it will provide a corporate update along with its financial results for Q2 2021 on August 5, 2021. The press release will be accessible after market close on their website. Vir focuses on combining immunologic insights with advanced technologies to combat serious infectious diseases, with a development pipeline that includes candidates targeting COVID-19, hepatitis B, influenza A, and HIV.
Vir Biotechnology announced on July 15, 2021, that the first patient has been dosed in the Phase 2 MARCH trial for VIR-2218 and VIR-3434, targeting chronic hepatitis B infection. This trial aims to assess the safety and efficacy of these investigational therapies, aiming for a functional cure in approximately 90 patients. The combination approach is expected to restore immune response against HBV, with primary endpoints focusing on treatment-emergent adverse events and achieving undetectable HBsAg. Both drugs utilize novel technologies that could enhance treatment effectiveness.
Vir Biotechnology announced promising results from Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 for chronic hepatitis B virus (HBV). Both therapies exhibited positive safety profiles and significant reductions in hepatitis B surface antigen (HBsAg). VIR-2218 showed dose-dependent HBsAg reductions and enhanced results when combined with pegylated interferon alfa. The Phase 1 trial of VIR-3434 indicated rapid HBsAg declines with no new safety concerns. A combination trial of both therapies is expected to start in the latter half of 2021.
FAQ
What is the current stock price of Vir Biotechnology (VIR)?
What is the market cap of Vir Biotechnology (VIR)?
What is Vir Biotechnology, Inc.?
What are the main focus areas of Vir Biotechnology?
How does Vir Biotechnology generate its revenue?
What recent achievements has Vir Biotechnology accomplished?
What diseases are targeted by Vir's product pipeline?
What is the significance of Vir's collaboration with Brii Biosciences?
How does Vir's technology platform work?
What are some characteristics of BRII-877 and BRII-835?
How does Vir approach treatment for chronic HBV infection?
What impact does Vir aim to have on global infectious disease treatment?
